Latest Period
Q1 2026
Security Snapshot
Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX) Institutional Ownership
CUSIP: 501976104
13F Institutional Holders and Ownership History from Q1 2024 to Q2 2026
Institutions Reporting
111
Shares (Excl. Options)
34,823,469
Price
$8.63
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.00001 per share
- Symbol
- KYTX on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 34,823,469
- Total 13F value
- $300,524,364
- Portfolio coverage rank
- 0%
- Share change
- +290,170
- Value change
- +$1,033,862
- Number of holders
- 111
- Shares outstanding
- 56,833,213
- SEC-reported price per share
- $8.91
- Insider filing price
- $8.91
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- KYTX - Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 501976104.
- 111 institutions reported positions in Q1 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 111 to 2 between Q1 2026 and Q2 2026.
- SEC-reported value moved from $300,524,364 to $3,786,661.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 111 institutions filings for Q1 2026.
Security key
501976104
Latest holder period
Q1 2026
13F holders
111
13D/G owners
4
CIK / CUSIP context first
Open Q1 2026 holders
KYTX full holder history
Kyverna Therapeutics, Inc. SEC filings
Kyverna Therapeutics, Inc. company facts
Kyverna Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 501976104:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
KYTX
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Westlake BioPartners Fund I, L.P. | 7.8% | $43,778,216 | 4,657,257 | Dr. Beth C. Seidenberg ("Seidenberg") | 31 Dec 2025 | |||
| Northpond Ventures III, LP | 6.1% | $28,531,978 | 3,466,826 | Michael P. Rubin | 31 Dec 2025 | |||
| Bain Capital Life Sciences Opportunities III, LP | 5.4% | $25,595,300 | 3,110,000 | Bain Capital Life Sciences Opportunities III, LP | 31 Dec 2025 | |||
| GordonMD Global Investments LP | 7% | $23,275,071 | 3,058,485 | GordonMD Global Investments LP | 13 Nov 2025 |
As of 31 Mar 2026, 111 institutional investors reported holding 34,823,469 shares of Kyverna Therapeutics, Inc. - Common Stock, par value $0.00001 per share (KYTX). This represents 61% of the company’s total 56,833,213 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
54%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GordonMD Global Investments LP | 7.5% | 4,244,818 | -3.3% | 32% | $36,632,779 |
| GILEAD SCIENCES, INC. | 7.3% | 4,126,119 | 0% | 1.7% | $35,608,407 |
| Bain Capital Life Sciences Investors, LLC | 5.5% | 3,110,000 | 0% | 2.4% | $26,839,300 |
| AIGH Capital Management LLC | 3.5% | 2,000,000 | +33% | 3.5% | $17,260,000 |
| DEERFIELD MANAGEMENT COMPANY, L.P. | 3.5% | 2,000,000 | 0% | 0.2% | $17,260,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.1% | 1,783,342 | 0% | 0% | $15,390,241 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.7% | 1,555,287 | -12% | 0% | $13,423,000 |
| Balyasny Asset Management L.P. | 2% | 1,125,321 | +15% | 0.02% | $9,711,520 |
| MILLENNIUM MANAGEMENT LLC | 1.8% | 1,005,508 | +69% | 0.01% | $8,677,534 |
| Insight Holdings Group, LLC | 1.7% | 989,054 | 0% | 0.6% | $8,535,536 |
| MORGAN STANLEY | 1.7% | 977,289 | -2.5% | 0% | $8,434,004 |
| BlackRock, Inc. | 1.5% | 877,078 | +61% | 0% | $7,569,182 |
| Woodline Partners LP | 1.5% | 845,325 | +0.02% | 0.03% | $7,295,155 |
| D. E. Shaw & Co., Inc. | 1.3% | 721,581 | +39% | 0% | $6,227,244 |
| Propel Bio Management, LLC | 1.1% | 644,421 | -3.3% | 3.5% | $5,585,588 |
| MBB PUBLIC MARKETS I LLC | 1.1% | 614,477 | 0% | 0.63% | $5,302,937 |
| MARSHALL WACE, LLP | 1.1% | 605,512 | +347% | 0.01% | $5,225,570 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1% | 577,600 | +142% | 0.01% | $4,984,688 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 0.88% | 500,000 | -70% | 0.01% | $4,315,000 |
| UBS Group AG | 0.79% | 449,750 | +122% | 0% | $3,881,342 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.75% | 423,826 | +59% | 0% | $3,659,534 |
| BNP PARIBAS FINANCIAL MARKETS | 0.72% | 412,032 | 0% | 0% | $3,555,836 |
| RENAISSANCE TECHNOLOGIES LLC | 0.65% | 367,492 | +107% | 0% | $3,171,456 |
| Qube Research & Technologies Ltd | 0.59% | 333,692 | +425% | 0% | $2,879,762 |
| VANGUARD FIDUCIARY TRUST CO | 0.4% | 224,584 | 0% | 0% | $1,938,160 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
10
Latest
Q1 2026
Rows shown
1-10 of 10
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 424,990 | $3,786,661 | +$1,221,053 | $8.91 | 2 |
| 2026 Q1 | 34,823,469 | $300,524,364 | +$1,033,862 | $8.63 | 111 |
| 2025 Q4 | 34,131,760 | $320,775,226 | +$111,162,333 | $9.40 | 99 |
| 2025 Q3 | 22,688,863 | $136,134,153 | -$2,158,017 | $6.00 | 74 |
| 2025 Q2 | 23,200,134 | $71,227,727 | -$5,373,744 | $3.07 | 77 |
| 2025 Q1 | 25,800,890 | $49,797,231 | -$8,775,592 | $1.93 | 86 |
| 2024 Q4 | 28,863,400 | $107,952,189 | -$6,920,913 | $3.74 | 87 |
| 2024 Q3 | 28,136,737 | $138,294,516 | -$28,965,516 | $4.89 | 92 |
| 2024 Q2 | 31,935,411 | $239,516,646 | -$86,044,405 | $7.50 | 87 |
| 2024 Q1 | 30,688,965 | $762,283,849 | +$760,773,578 | $24.84 | 88 |